<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00849355</url>
  </required_header>
  <id_info>
    <org_study_id>ADOPEH-LINFMYO-2007</org_study_id>
    <nct_id>NCT00849355</nct_id>
  </id_info>
  <brief_title>Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk</brief_title>
  <official_title>Phase II, Multicenter Trial to Evaluate the Efficacy and Safety of the Following Treatment Squeme:Ciclophosphamide, Vincristine, Lyposomal Doxorrubicine, Myocet and Prednisone,Combined With Rituximab in First Line Treatment for Patients With Aggresive No Hodgkin B Lymphoma and Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociacion Doctor Peset Para el Estudio de la Hematología</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pivotal S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asociacion Doctor Peset Para el Estudio de la Hematología</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy (and safety) of the following treatment
      squeme:Ciclophosphamide, Vincristine, lyposomal Doxorrubicine (Myocet) and
      Prednisone,combined with Rituximab in first line treatment for patients with aggresive No
      Hodgkin B lymphoma and cardiovascular risk
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II, multicenter, open , 1-arm study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">November 2010</completion_date>
  <primary_completion_date type="Anticipated">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate treatment efficacy by measuring response to treatment</measure>
    <time_frame>at the end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluate cardiotoxicity and tolerability</measure>
    <time_frame>At the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate progression free survival</measure>
    <time_frame>At the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate event free survival</measure>
    <time_frame>At the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate tumor free survival</measure>
    <time_frame>At the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate overall survival</measure>
    <time_frame>At the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate response duration</measure>
    <time_frame>At the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment adherence</measure>
    <time_frame>At the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>At the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dose intensity and relative dose intensity</measure>
    <time_frame>At the end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>No Hodgkin B Lymphoma</condition>
  <arm_group>
    <arm_group_label>unique</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RCOMP-14 with Rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RCOMP-14 + rituximab</intervention_name>
    <description>Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.
Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d. Prednisone 100 mg/d from day 1 to 5 and every 14 d.</description>
    <arm_group_label>unique</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histological diagnosis of Lymphoma no Hodgkin B CD20+ high degree of
             mailgnancy

          2. Patients no previously treated

          3. stage III o IV

          4. Informed consent

          5. At least one measurable injury

          6. Age &gt;18

          7. ECOG 0-2

          8. Life expectancy &gt;6 months

          9. Cardiovascular risk defined as:Mild-moderate systolic dysfunction,isquemic
             cardiopathy, diabetes mellitus, hypertension,left ventricular hypertrophy, cardiac
             arrhythmia, moderate pulmonar hypertension

         10. adequate organic functionallity (creatinine&lt;2mg/dl;bilirubin&lt;2mg/dl; ALT-AST-FA&lt;5 FSN;
             neutrphyls total count &gt;1.5x 109/l and platellet count &gt;100x1097l)

         11. Use of a contraceptive method during study + 3 months -

        Exclusion Criteria:

          1. stage I or II with IPI=0

          2. Symptomatic tumoral affection of Nervous central system

          3. Lymphoma no hodgkin B indolent

          4. Lymphoma no hodgkin B mantle-cell

          5. Lymphoma no hodgkin T

          6. lymphoprolifertaive syndrome post-transplantation or immunosuppression associated

          7. cardiovacualr disease symptomatic

          8. Cronic infection or acute serious

          9. history of neoplasia in past 5 years

         10. not able to understand the study or poor protocol adherence

         11. Known Hypersensivity to any atudy drug

         12. pregnant/lactant women

         13. Previous participation in clinicla study in past 30 days

         14. Previous treatment with antraciclines or any drug used in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Secundino Ferrer</last_name>
    <phone>+34961622536</phone>
    <email>ferrer_sec@gva.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felix Carbonell</last_name>
    <phone>+34961972000</phone>
    <email>carbonell_fel@gav.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Vall D'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Castellon</name>
      <address>
        <city>Castellon</city>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Severo Ochoa</name>
      <address>
        <city>Madrid</city>
        <zip>28211</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pedro Sanchez</last_name>
      <phone>+34914818000</phone>
      <email>psanchez.hsvo@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28220</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Getafe</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose García</last_name>
      <phone>+34916839360</phone>
      <email>garciavela.joseantonio@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital son Llatzer</name>
      <address>
        <city>Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Messeguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Sanchez</last_name>
      <phone>+34606388315</phone>
      <email>josej.sanchezz3@carm.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Mª del Rosell</name>
      <address>
        <city>Murcia</city>
        <zip>30203</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Martinez</last_name>
      <phone>+34968504800</phone>
      <email>amartifran@ono.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital general universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2009</study_first_posted>
  <last_update_submitted>February 20, 2009</last_update_submitted>
  <last_update_submitted_qc>February 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Secundino Ferrer</name_title>
    <organization>Asociacion Doctor Peset Para el Estudio de la Hematología</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

